Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD4 in Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma
NCT00877656Phase 3Completed
- Sponsor
- Emergent BioSolutions
- Start
- Aug 2005
- Primary completion
- Jan 2006
01
Overview
A Phase 3 trial of zanolimumab in myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement, sponsored by Emergent BioSolutions. Started Aug 2005; status: completed.
02
Drugs
zanolimumab
03
Conditions
myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement
Beyond the preview
Go deeper on NCT00877656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877656.